CGRP and migraine: from bench to bedside
- PMID: 34275653
- DOI: 10.1016/j.neurol.2021.06.003
CGRP and migraine: from bench to bedside
Abstract
Migraine treatment has reached a new era with the development of drugs that target the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP related therapies offer considerable improvements over existing drugs as they are the first to be designed to act on the trigeminal pain system, more specific and with few adverse events. Small molecule CGRP receptor antagonists, such as rimegepant and ubrogepant, are effective for the acute treatment of migraine headache. In contrast, monoclonal antibodies against CGRP or the CGRP receptor are beneficial for the prophylactic treatments in chronic migraine. Here I will provide a historical overview of the long path that led to their successful development. In addition, I will discuss aspects on the biology of CGRP signalling, the role of CGRP in migraine headache, the efficacy of CGRP targeted treatment, and synthesize what currently is known about the role of CGRP in the trigeminovascular system.
Keywords: CGRP; CLR; CTR; RAMPs; Receptors.
Copyright © 2021 The Author. Published by Elsevier Masson SAS.. All rights reserved.
Similar articles
-
CGRP as the target of new migraine therapies - successful translation from bench to clinic.Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1. Nat Rev Neurol. 2018. PMID: 29691490 Review.
-
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22. Headache. 2018. PMID: 30242830 Review.
-
Role of CGRP in Migraine.Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201. Handb Exp Pharmacol. 2019. PMID: 30725283
-
Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.Headache. 2019 Jun;59(6):951-970. doi: 10.1111/head.13510. Epub 2019 Apr 25. Headache. 2019. PMID: 31020659 Review.
-
[Novel migraine treatment with CGRP-related monoclonal antibodies].Rinsho Shinkeigaku. 2020 Oct 24;60(10):668-676. doi: 10.5692/clinicalneurol.cn-001469. Epub 2020 Sep 5. Rinsho Shinkeigaku. 2020. PMID: 32893246 Review. Japanese.
Cited by
-
Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS Pharmacol Transl Sci. 2024 Mar 16;7(4):951-966. doi: 10.1021/acsptsci.3c00370. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633587 Review.
-
Electroacupuncture attenuates nociceptive behaviors in a mouse model of cancer pain.Mol Pain. 2024 Jan-Dec;20:17448069241240692. doi: 10.1177/17448069241240692. Mol Pain. 2024. PMID: 38443317 Free PMC article.
-
Neuropathic Corneal Pain after Coronavirus Disease 2019 (COVID-19) Infection.Diseases. 2024 Feb 9;12(2):37. doi: 10.3390/diseases12020037. Diseases. 2024. PMID: 38391784 Free PMC article.
-
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.J Headache Pain. 2024 Feb 5;25(1):16. doi: 10.1186/s10194-024-01723-4. J Headache Pain. 2024. PMID: 38311738 Free PMC article. Review.
-
A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine.Cureus. 2023 Nov 2;15(11):e48160. doi: 10.7759/cureus.48160. eCollection 2023 Nov. Cureus. 2023. PMID: 38046695 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials